A novel T7 RNA polymerase autogene for efficient cytoplasmic expression of target genes

M. Brisson, Yukai He, S. Li, J. P. Yang, L. Huang

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Inefficient nuclear transport of plasmid DNA continues to be a problem in nonviral vector-mediated gene transfer. This has made the cytoplasmic expression system an increasingly attractive idea. We have developed a new T7 RNA polymerase autogene for cytoplasmic expression containing both a CMV and a T7 promoter. The pCMV/T7-T7pol autogene does not encounter the problems associated with previously used autogenes. For instance, pCMV/T7-T7pol is easily amplified and purified from bacteria. Furthermore, the CMV promoter is used to drive the first round of synthesis of T7 RNA polymerase, thus negating the use of purified enzyme in the transfection complex. The endogenous T7 RNA polymerase produced from the CMV promoter could then act on the T7 promoter of pCMV/T7-T7pol in an autoregulatory mechanism. pCMV/T7-T7pol induces higher, more sustained levels (> 7 days) of reporter gene expression than that observed with the previously used autogene pT7 AUTO 2C- or with the nuclear expression system pCMV-CAT. This seems to be due to the high levels of T7 RNA polymerase protein that are detected in cells transfected with pCMV/T7-T7pol. This vector also functions as an efficient autogene since at least 50 times more mRNA is transcribed from the cytoplasmic T7 promoter as compared with the nuclear CMV promoter in pCMV/T7-T7pol. Therefore, pCMV/T7-T7pol could replace existing autogenes for regeneration of T7 RNA polymerase and efficient target gene expression.

Original languageEnglish (US)
Pages (from-to)263-270
Number of pages8
JournalGene Therapy
Volume6
Issue number2
DOIs
StatePublished - Feb 1 1999
Externally publishedYes

Fingerprint

Gene Expression
Cell Nucleus Active Transport
Reporter Genes
Transfection
Regeneration
Plasmids
bacteriophage T7 RNA polymerase
Bacteria
Messenger RNA
DNA
Enzymes
Genes
Proteins

Keywords

  • Autogene
  • Cytoplasmic expression
  • Gene therapy
  • T7 RNA polymerase

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

A novel T7 RNA polymerase autogene for efficient cytoplasmic expression of target genes. / Brisson, M.; He, Yukai; Li, S.; Yang, J. P.; Huang, L.

In: Gene Therapy, Vol. 6, No. 2, 01.02.1999, p. 263-270.

Research output: Contribution to journalArticle

Brisson, M. ; He, Yukai ; Li, S. ; Yang, J. P. ; Huang, L. / A novel T7 RNA polymerase autogene for efficient cytoplasmic expression of target genes. In: Gene Therapy. 1999 ; Vol. 6, No. 2. pp. 263-270.
@article{b9e9a1bfbe014948beacd8726e9faab1,
title = "A novel T7 RNA polymerase autogene for efficient cytoplasmic expression of target genes",
abstract = "Inefficient nuclear transport of plasmid DNA continues to be a problem in nonviral vector-mediated gene transfer. This has made the cytoplasmic expression system an increasingly attractive idea. We have developed a new T7 RNA polymerase autogene for cytoplasmic expression containing both a CMV and a T7 promoter. The pCMV/T7-T7pol autogene does not encounter the problems associated with previously used autogenes. For instance, pCMV/T7-T7pol is easily amplified and purified from bacteria. Furthermore, the CMV promoter is used to drive the first round of synthesis of T7 RNA polymerase, thus negating the use of purified enzyme in the transfection complex. The endogenous T7 RNA polymerase produced from the CMV promoter could then act on the T7 promoter of pCMV/T7-T7pol in an autoregulatory mechanism. pCMV/T7-T7pol induces higher, more sustained levels (> 7 days) of reporter gene expression than that observed with the previously used autogene pT7 AUTO 2C- or with the nuclear expression system pCMV-CAT. This seems to be due to the high levels of T7 RNA polymerase protein that are detected in cells transfected with pCMV/T7-T7pol. This vector also functions as an efficient autogene since at least 50 times more mRNA is transcribed from the cytoplasmic T7 promoter as compared with the nuclear CMV promoter in pCMV/T7-T7pol. Therefore, pCMV/T7-T7pol could replace existing autogenes for regeneration of T7 RNA polymerase and efficient target gene expression.",
keywords = "Autogene, Cytoplasmic expression, Gene therapy, T7 RNA polymerase",
author = "M. Brisson and Yukai He and S. Li and Yang, {J. P.} and L. Huang",
year = "1999",
month = "2",
day = "1",
doi = "10.1038/sj.gt.3300827",
language = "English (US)",
volume = "6",
pages = "263--270",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - A novel T7 RNA polymerase autogene for efficient cytoplasmic expression of target genes

AU - Brisson, M.

AU - He, Yukai

AU - Li, S.

AU - Yang, J. P.

AU - Huang, L.

PY - 1999/2/1

Y1 - 1999/2/1

N2 - Inefficient nuclear transport of plasmid DNA continues to be a problem in nonviral vector-mediated gene transfer. This has made the cytoplasmic expression system an increasingly attractive idea. We have developed a new T7 RNA polymerase autogene for cytoplasmic expression containing both a CMV and a T7 promoter. The pCMV/T7-T7pol autogene does not encounter the problems associated with previously used autogenes. For instance, pCMV/T7-T7pol is easily amplified and purified from bacteria. Furthermore, the CMV promoter is used to drive the first round of synthesis of T7 RNA polymerase, thus negating the use of purified enzyme in the transfection complex. The endogenous T7 RNA polymerase produced from the CMV promoter could then act on the T7 promoter of pCMV/T7-T7pol in an autoregulatory mechanism. pCMV/T7-T7pol induces higher, more sustained levels (> 7 days) of reporter gene expression than that observed with the previously used autogene pT7 AUTO 2C- or with the nuclear expression system pCMV-CAT. This seems to be due to the high levels of T7 RNA polymerase protein that are detected in cells transfected with pCMV/T7-T7pol. This vector also functions as an efficient autogene since at least 50 times more mRNA is transcribed from the cytoplasmic T7 promoter as compared with the nuclear CMV promoter in pCMV/T7-T7pol. Therefore, pCMV/T7-T7pol could replace existing autogenes for regeneration of T7 RNA polymerase and efficient target gene expression.

AB - Inefficient nuclear transport of plasmid DNA continues to be a problem in nonviral vector-mediated gene transfer. This has made the cytoplasmic expression system an increasingly attractive idea. We have developed a new T7 RNA polymerase autogene for cytoplasmic expression containing both a CMV and a T7 promoter. The pCMV/T7-T7pol autogene does not encounter the problems associated with previously used autogenes. For instance, pCMV/T7-T7pol is easily amplified and purified from bacteria. Furthermore, the CMV promoter is used to drive the first round of synthesis of T7 RNA polymerase, thus negating the use of purified enzyme in the transfection complex. The endogenous T7 RNA polymerase produced from the CMV promoter could then act on the T7 promoter of pCMV/T7-T7pol in an autoregulatory mechanism. pCMV/T7-T7pol induces higher, more sustained levels (> 7 days) of reporter gene expression than that observed with the previously used autogene pT7 AUTO 2C- or with the nuclear expression system pCMV-CAT. This seems to be due to the high levels of T7 RNA polymerase protein that are detected in cells transfected with pCMV/T7-T7pol. This vector also functions as an efficient autogene since at least 50 times more mRNA is transcribed from the cytoplasmic T7 promoter as compared with the nuclear CMV promoter in pCMV/T7-T7pol. Therefore, pCMV/T7-T7pol could replace existing autogenes for regeneration of T7 RNA polymerase and efficient target gene expression.

KW - Autogene

KW - Cytoplasmic expression

KW - Gene therapy

KW - T7 RNA polymerase

UR - http://www.scopus.com/inward/record.url?scp=0032991780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032991780&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3300827

DO - 10.1038/sj.gt.3300827

M3 - Article

C2 - 10435111

AN - SCOPUS:0032991780

VL - 6

SP - 263

EP - 270

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 2

ER -